The company also said in a press release the vaccine demonstrated "significant clinical efficacy" against both the rapidly emerging variants of the virus first identified in
The phase three clinical trial in
Of the 62 cases diagnosed with COVID-19, the disease caused by the virus, six had received the vaccine and the rest had been administered a placebo, signaling an efficacy rate of 89.3 percent, the company based in
A preliminary analysis also indicated that the vaccine was 85.6 percent effective against the British strain.
Meanwhile, a mid-stage clinical trial in
In
==Kyodo
© Kyodo News International, Inc., source